Stockreport

Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

Deciphera Pharmaceuticals, Inc.  (DCPH) 
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: deciphera.com/investor-relations
PDF - INVICTUS Achieved Primary Endpoint, Ripretinib Significantly Improved Progression Free Survival (PFS) Versus Placebo in Patients with Fourth-line and Fourth-line Plus [Read more]